A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Trial Profile

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs THX-110 (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2017 According to Therapix Biosciences Ltd. media release, status changed from recruiting to active, no longer recruiting.
    • 09 Nov 2017 According to Therapix Biosciences media release, 17 patients have been enrolled in the trial to date. The final patient is currently projected to be enrolled later this month.
    • 10 Aug 2017 According to Therapix Biosciences media release, in this trial the patients who have completed the initial 3-month treatment period have been given the option to extend their treatment for an additional 3 months based on a positive assessment of efficaciousness after the first 3 months. Till now, 8 patients have opted to extend their treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top